Quantcast
Home > Quotes > EPZM
EPZM

Epizyme, Inc. Common Stock (EPZM) Quote & Summary Data

$21.79
*  
0.02
0.09%
Get EPZM Alerts
*Delayed - data as of Jan. 29, 2020 10:55 ET  -  Find a broker to begin trading EPZM now
Exchange:NASDAQ
Industry: Health Care
View:    EPZM Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 21.74 / $ 21.79
1 Year Target
29
Today's High / Low
$ 22.02 / $ 21.44
Share Volume
212,351
50 Day Avg. Daily Volume
1,198,052
Previous Close
$ 21.81
52 Week High / Low
$ 27.82 / $ 9.04
Market Cap
2,129,767,870
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.61
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1

Intraday Chart

Shares Traded

Share Volume:
212,351
50 Day Avg. Daily Volume:
1,198,052

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.61

Trading Range

The current last sale of $21.79 is 141.04% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 22.02 $ 27.82
 Low: $ 21.44 $ 9.04

Company Description (as filed with the SEC)

We are a late-stage biopharmaceutical company that is committed to rewriting treatment for people with cancer and other serious diseases through the discovery, development, and commercialization of novel epigenetic medicines. By focusing on the genetic drivers of disease, our science seeks to match targeted medicines with the patients who need them. We are developing our lead product candidate, tazemetostat, an oral, first-in-class, selective small molecule inhibitor of the EZH2 histone methyltransferase, or HMT, for the treatment of a broad range of cancer types in multiple treatment settings, and developing our novel G9a program, EZM8266, for the treatment of sickle cell disease, or SCD. We have taken a "pipeline in a product" approach to developing tazemetostat with a broad clinical development program through company-sponsored studies and collaborations.  ... More ...  



Risk Grade

Where does EPZM fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 21.98
Open Date:
Jan. 29, 2020
Close Price:
N/A
Close Date:
N/A


Consensus Recommendation

Analyst Info